Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies

Background: asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose–response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and 45 μg/m(2) as optimal biological and maximum-toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Mammoliti, S., Andretta, V., Bennicelli, E., Caprioni, F., Comandini, D., Fornarini, G., Guglielmi, A., Pessino, A., Sciallero, S., Sobrero, A. F., Mazzola, G., Lambiase, A., Bordignon, C.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065876/
https://www.ncbi.nlm.nih.gov/pubmed/20855468
http://dx.doi.org/10.1093/annonc/mdq436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065876/
https://www.ncbi.nlm.nih.gov/pubmed/20855468
http://dx.doi.org/10.1093/annonc/mdq436

Ejemplares similares